Skip to main content
    I

    Illumina Inc (ILMN)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $198.00
    -9.01 (-4.35%)

    Market Cap: $31.30B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Illumina Inc (ILMN) Earnings: Report Dates and Results

    Updated Oct 29, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Illumina (ILMN) is expected to report earnings on Feb 3, 2027. In the quarter ended Sep 30, 2026, Illumina reported EPS of $1.44, above the $1.36 estimate. It beat the EPS estimate in 7 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    79%(31/39)
    Avg Surprise
    +18.89%
    Streak
    7 Q

    Upcoming Estimates

    Reports Feb 3, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$1.56
    Range$1.48 - $1.64
    20 analysts
    Revenue Consensus
    $1.25B
    Range$1.19B - $1.30B
    20 analysts
    Reports Apr 28, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$1.35
    Range$1.28 - $1.53
    13 analysts
    EPS Revisions
    2
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$1.33+1.8%
    60d ago$1.32+1.9%
    30d ago$1.33+1.8%
    7d ago$1.35-0.1%
    Current$1.35
    Revenue Consensus
    $1.16B
    Range$1.14B - $1.19B
    9 analysts

    Next Report

    ILMN has an expected report date of Feb 3, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 15.6% above the $1.35 reported for the quarter ended Dec 31, 2025.

    ILMN Earnings Call

    The latest ILMN earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 39 quarters below that had an estimate, ILMN beat 31, missed 7 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $1.13B, up 4.6% from $1.08B a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$1.44$1.36$1.34 - $1.38+5.88%Beat+7.5%191 up, 0 downOct 29, 2026$1.13B
    Jun 30, 2026$1.31$1.23$1.20 - $1.26+6.50%Beat+10.1%172 up, 0 downJul 30, 2026$1.16B
    Mar 31, 2026$1.15$1.06$1.04 - $1.08+8.49%Beat+18.6%170 up, 3 downApr 30, 2026$1.09B
    Dec 31, 2025$1.35$1.23$1.18 - $1.29+9.76%Beat+57.0%163 up, 2 downFeb 5, 2026$1.16B
    Sep 30, 2025$1.34$1.17$1.12 - $1.19+14.53%Beat+17.5%182 up, 4 downOct 30, 2025$1.08B
    Jun 30, 2025$1.19$1.01$0.96 - $1.05+17.82%Beat+230.6%204 up, 0 downJul 31, 2025$1.06B
    Mar 31, 2025$0.97$0.94$0.83 - $0.97+3.19%Beat+977.8%194 up, 4 downMay 8, 2025$1.04B
    Dec 31, 2024$0.86$0.92$0.91 - $0.93-6.52%Miss+514.3%101 up, 0 downFeb 6, 2025$1.10B
    Sep 30, 2024$1.14$0.88$0.84 - $0.97+29.55%Beat+245.5%202 up, 1 downNov 4, 2024$1.08B
    Jun 30, 2024$0.36$0.90$0.83 - $0.96-60.00%Miss+12.5%104 up, 1 downAug 6, 2024$1.11B
    Mar 31, 2024$0.09$0.11-$0.11 - $0.25-18.18%Miss+12.5%152 up, 0 downMay 2, 2024$1.08B
    Dec 31, 2023$0.14$0.12-$0.11 - $0.18+16.67%Beat0.0%168 up, 0 downFeb 8, 2024$1.12B
    Sep 30, 2023$0.33$0.14-$0.03 - $0.20+135.71%Beat-2.9%160 up, 2 downNov 9, 2023$1.12B
    Jun 30, 2023$0.32$0.02$0.00 - $0.08N/AN/A-43.9%140 up, 0 downAug 9, 2023$1.18B
    Mar 31, 2023$0.08$0.03$0.00 - $0.12+166.67%Beat-92.5%150 up, 0 downApr 25, 2023$1.09B
    Dec 31, 2022$0.14$0.19-$0.23 - $0.48-26.32%Miss-81.3%162 up, 3 downFeb 7, 2023$1.08B
    Sep 30, 2022$0.34$0.30$0.21 - $0.48+13.33%Beat-76.6%150 up, 0 downNov 3, 2022$1.11B
    Jun 30, 2022$0.57$0.64$0.53 - $0.89-10.94%Miss-69.5%150 up, 0 downAug 11, 2022$1.16B
    Mar 31, 2022$1.07$0.89$0.75 - $0.98+20.22%Beat-43.4%130 up, 0 downMay 5, 2022$1.22B
    Dec 31, 2021$0.75$0.49$0.32 - $0.62+53.06%Beat-38.5%166 up, 0 downFeb 10, 2022$1.20B
    Sep 30, 2021$1.45$1.22$0.89 - $1.36+18.85%Beat+42.2%11N/ANov 4, 2021$1.11B
    Jun 30, 2021$1.87$1.36$1.31 - $1.41+37.50%Beat+201.6%17N/AAug 5, 2021$1.13B
    Mar 31, 2021$1.89$1.40$1.17 - $1.94+35.00%Beat+15.2%17N/AApr 27, 2021$1.09B
    Dec 31, 2020$1.22$1.11$1.01 - $1.23+9.91%Beat-28.2%17N/AFeb 11, 2021$953.00M
    Sep 30, 2020$1.02$0.80$0.67 - $0.89+27.50%Beat-47.2%16N/AOct 29, 2020$794.00M
    Jun 30, 2020$0.62$0.67$0.33 - $1.06-7.46%Miss-54.1%16N/AAug 6, 2020$633.00M
    Mar 31, 2020$1.64$1.25$1.17 - $1.32+31.20%Beat+2.5%16N/AApr 30, 2020$859.00M
    Dec 31, 2019$1.70$1.58$1.55 - $1.64+7.59%Beat+28.8%17N/AJan 29, 2020$952.00M
    Sep 30, 2019$1.93$1.41$1.34 - $1.48+36.88%Beat+27.0%14N/AOct 24, 2019$907.00M
    Jun 30, 2019$1.35$1.34$1.13 - $1.70+0.75%Beat-5.6%15N/AJul 29, 2019$838.00M
    Mar 31, 2019$1.60$1.35$1.27 - $1.39+18.52%Beat+10.3%15N/AApr 25, 2019$846.00M
    Dec 31, 2018$1.32$1.36$1.32 - $1.47-2.94%Miss-8.3%16N/AJan 29, 2019$1.50B
    Sep 30, 2018$1.52$1.26$1.17 - $1.40+20.63%Beat+36.9%18N/AOct 23, 2018$853.00M
    Jun 30, 2018$1.43$1.11$1.07 - $1.16+28.83%Beat+74.4%18N/AJul 30, 2018$830.00M
    Mar 31, 2018$1.45$1.02$0.85 - $1.09+42.16%Beat+126.6%18N/AApr 24, 2018$154.00M
    Dec 31, 2017$1.44$1.21$1.14 - $1.33+19.01%Beat+69.4%18N/AJan 30, 2018$778.00M
    Sep 30, 2017$1.11$0.99$0.92 - $1.07+12.12%Beat+14.4%17N/AOct 24, 2017$714.00M
    Jun 30, 2017$0.82$0.69$0.64 - $0.75+18.84%Beat-4.7%17N/AAug 1, 2017$662.00M
    Mar 31, 2017$0.64$0.64N/A0.00%In line-9.9%N/AN/AApr 25, 2017$598.00M
    Dec 31, 2016$0.85$0.83N/A+2.41%Beat+4.9%N/AN/AJan 31, 2017$619.00M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $4.85, up 98.0% from the year before. It was $3.39 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$4.85+98.0%
    Dec 31, 2024$2.45+181.6%
    Dec 31, 2023$0.87-59.0%
    Dec 31, 2022$2.12-64.4%
    Dec 31, 2021$5.96+32.4%
    Dec 31, 2020$4.50-31.6%
    Dec 31, 2019$6.58+15.0%
    Dec 31, 2018$5.72+42.6%
    Dec 31, 2017$4.01+18.3%
    Dec 31, 2016$3.39N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,000 words across 16 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20267,99416
    2026Q2Jun 30, 20266,41514
    2026Q1Mar 31, 20267,72118
    2025Q4Dec 31, 20257,51713
    2025Q3Sep 30, 20257,28516
    2025Q2Jun 30, 20256,17811
    2025Q1Mar 31, 20257,26113
    2024Q4Dec 31, 20248,49917

    2026Q3 Earnings Call

    Opening remarks

    Conor McNamara Head of Investor Relations Hello, everyone, and welcome to Illumina's third quarter 2026 earnings call. Today, we will review our financial results released after the market close and provide prepared remarks before opening the line for Q&A. Our earnings release is available in the investor relations section of illumina.com. Joining me today are Jacob Thaysen, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer. Jacob will begin with an update on Illumina's business, followed by Ankur's review of our financials. As you may have seen in our press release, we recognized certain tariff refunds in the third quarter, which had a positive impact on GAAP and non-GAAP operating income, margins, and EPS, and a negative impact on revenue. These refunds were not contemplated in our previous guidance, and all financial measures discussed today will be on an adjusted non-GAAP basis, excluding the impact of tariff refunds. Reconciliations to non-GAAP and GAAP can be found in today's release and in the supplementary data on our website. All revenue and revenue growth rates are presented excluding tariff refunds. Organic revenue growth also adjusts for the impact of currency and acquisitions, and rest-of-world organic growth further excludes our Greater China region. This call is being recorded, and the replay will be available on our website. As a reminder, the information provided and discussed today will include forward-looking statements, including statements about Illumina's future events, product outlook, and financial expectations. Actual results may differ materially. To better understand the risks and uncertainties that could cause actual results to differ, we refer you to the documents that Illumina files with the SEC, including our most recent Forms 10-Q and 10-K. With that, I will now turn the call over to Jacob.

    Jacob Thaysen CEO Thank you, Conor, and good afternoon, everyone. We had a great third quarter with strong clinical sequencing demand and elevated NovaSeq X placements, driving revenue, margin, and EPS above our guidance range. Our strategy is working, and I'm proud of what our team delivered for our customers and shareholders. Our continued disciplined execution and business momentum allow us to raise our fiscal year guidance, and we remain on track to achieve our long-range financial targets. Before I go into details on our results, I want to highlight a few ways our innovation is helping customers answer new questions about biology. Early in 2026, we introduced the Billion Cell Atlas to address one of the biggest bottlenecks in applying AI to biology: the lack of functional data sets. AI models need large amounts of data to learn from. In biology, those models only work if the data is accurate, standardized, and reproducible. These data sets don't exist at scale. There is no internet of biology.

    Frequently Asked Questions About ILMN

    When is Illumina's next earnings date?

    Illumina's next earnings report is expected for Feb 3, 2027.

    Did ILMN beat earnings estimates last quarter?

    Yes. Illumina reported EPS of $1.44 for the quarter ended Sep 30, 2026, above the $1.36 estimate, a 5.88% surprise.

    What EPS do analysts expect from ILMN next quarter?

    The consensus EPS estimate for Illumina for the quarter ending Dec 31, 2026 is $1.56 from 20 analysts, with estimates from $1.48 to $1.64.

    How often does ILMN beat earnings estimates?

    Illumina beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +7.46%.